Market research
EYPT EyePoint, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 420M
- P/E ratio
- Not available
- Analyst target
- 27.3636
- Dividend yield
- Not available
- Beta
- 1.74
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US30233G2093
- Market cap
- 420M
- P/E ratio
- Not available
- Analyst target
- 27.3636
- Dividend yield
- Not available
- Beta
- 1.74
About
About EyePoint, Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EYPT discussion.
5 years, 4 months ago
EyePoint Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
EyePoint Pharmaceuticals, Inc's total revenue sank by 17.4% to $7M since the same quarter in the previous year.
Its net income has dropped by 48.6% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 149.6% to $6M since the same quarter in the previous year.
Based on the above factors, EyePoint Pharmaceuticals, Inc gets an overall score of 2/5.